A pseudoatrophy effect has been held responsible for the lack of net impact of natalizumab on brain volume outcomes in 2-year trials, but no data are available beyond 24 months.
Objective:
We aimed to investigate brain volume dynamics in natalizumab-treated patients in up to 3 years after therapy initiation with clinical correlations.
Methods:
Patients on natalizumab for at least 3 years were clinically assessed 3-monthly. Magnetic resonance imaging scans were performed at baseline and yearly. Brain volume changes were obtained with SIENA. Multivariate models were used to investigate the association between baseline inflammation and changes in brain volume and disability.
Results:
Sixty-two patients with multiple sclerosis were analysed. Mean age and disease duration were 34.7 (SD: 8.3) and 10.4 (SD: 6.6) years. Presence of gadolinium enhancement at baseline was not associated with Expanded Disability Status Scale changes (p=0.468), but was associated with larger brain volume decreases (p=0.005) in the first (p=0.024) and second year (p=0.019) but not in the third year (p=0.863). Brain volume changes at 12 and 36 months were marginally associated with disability status at month 12 (p=0.094) and 36 (p=0.084), respectively.
Conclusions:
Baseline inflammation affects brain volume measures up to 24 months after natalizumab initiation. A marginal association of brain volume changes with disability is present.
BjartmarCTrappBD. Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. Curr Opin Neurol2001; 14: 271–278.
2.
BermelRABakshiR. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol2006; 5: 158–170.
3.
RazNRodrigueKM. Differential aging of the brain: Patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev2006; 30: 730–748.
4.
FisherELeeJCNakamuraK. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol2008; 64: 255–265.
5.
De StefanoNGiorgioABattagliniM. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology2010; 74: 1868–1876.
6.
Perez-MirallesFSastre-GarrigaJTintoreM. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler2013; 19: 1878-1886.
7.
LosseffNAWangLLaiHM. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain1996; 119: 2009–2019.
8.
Sastre-GarrigaJIngleGTRovarisM. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. Neurology2005; 65: 633–635.
9.
ComiGMartinelliVRodegherM. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet2009; 374: 1503–1511.
10.
KapposLFreedmanMSPolmanCH. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet2007; 370: 389–397.
11.
RudickRAFisherELeeJC. Brain atrophy in relapsing multiple sclerosis: Relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler2000; 6: 365–372.
12.
RovarisMComiGRoccaMA. Short-term brain volume change in relapsing–remitting multiple sclerosis: Effect of glatiramer acetate and implications. Brain2001; 124: 1803–1812.
13.
MolyneuxPDKapposLPolmanC. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain2000; 123: 2256–2263.
14.
MontalbanXSastre-GarrigaJTintoreM. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler2009; 15: 1195–1205.
15.
WolinskyJSNarayanaPAO’ConnorP. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol2007; 61: 14–24.
16.
LearySMMillerDHStevensonVL. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology2003; 60: 44–51.
17.
FilippiMRovarisMIngleseM. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet2004; 364: 1489–1496.
18.
ZivadinovRStosicMCoxJL. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol2008; 255(Suppl 1): 61–74.
19.
MillerDHSoonDFernandoKT. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology2007; 68: 1390–1401.
20.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
21.
KapposLRadueEWO’ConnorP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
22.
ComiGJefferyDKapposL. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med2012; 366: 1000–1009.
23.
CohenJAColesAJArnoldDL. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
24.
ColesAJTwymanCLArnoldDL. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
25.
ZivadinovRRederATFilippiM. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology2008; 71: 136–144.
26.
SormaniMPArnoldDLDe StefanoN. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol2014; 75: 43-49.
27.
Vidal-JordanaASastre-GarrigaJPerez-MirallesF. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler2013; 19: 1175–1181.
28.
HorgaACastilloJRioJ. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol2011; 52: 321–330.
29.
SmithSMDe StefanoNJenkinsonM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr2001; 25: 466–475.
30.
MagranerMCoretFCasanovaB. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. Eur J Radiol2012; 81: 3485–3490.
31.
PortaccioEStromilloMLGorettiB. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing–remitting multiple sclerosis: A prospective, non-randomized pilot study. Eur J Neurol2013; 20: 986–990.
32.
RinaldiFCalabreseMSeppiD. Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis. Mult Scler2012; 18: 1760–1767.
33.
FisherERudickRASimonJH. Eight-year follow-up study of brain atrophy in patients with MS. Neurology2002; 59: 1412–1420.
34.
TrappBDPetersonJRansohoffRM. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338: 278–285.
35.
BorrielloGProsperiniLMarinelliF. Observations during an elective interruption of natalizumab treatment: A post-marketing study. Mult Scler2011; 17: 372–375.
36.
VrenkenHJenkinsonMHorsfieldMA. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol2013; 260: 2458–2471.
